ARV Class | PIs†§ | NNRTIs | NRTIs | Other |
|---|
ARVs | LPV/r (401) | EFV (399) | 3TC (654) | RAL (104) |
FPV/r (187) | NVP (164) | TDF (604) | MVC (22) |
SQVr (158) | ETR (28) | d4T (587) | ENF (48) |
IDV/r (129) | DLV (15) | ddI (511) | |
ATV/r (120) | | ABC (435) | |
NFV (100) | | AZT (260) | |
DRV/r (81) | | FTC (185) | |
TPV/r (27) | | | |
Total | 1,203 | 606 | 3,236 | 174 |
- *The number within parenthesis following an individual ARV indicates the number of TCEs in which the ARV was included in the salvage therapy regimen.
- † “/r” indicates ritonavir-boosting.
- §Included among the 187 TCEs listed as having received FPV/r are 76 who received unboosted FPV or APV; Included among the 158 TCEs listed as having received SQV/r are 23 who received unboosted SQV; Included among the 129 TCEs listed as having received IDV/r are 34 who received unboosted IDV; Included among the 120 TCEs listed as having received ATV/r are 4 who received unboosted ATV.
- Abbreviations: PI protease inhibitor; NRTI nucleoside RT inhibitor; NNRTI non-nucleoside RT inhibitor; LPV lopinavir; FPV fosamprenavir; SQV saquinavir; IDV indinavir; ATV atazanavir; NFV nelfinavir; DRV darunavir; TPV tipranavir; EFV efavirenz; NVP nevirapine; ETR etravirine; DLV delavirdine; 3TC lamivudine; TDF tenofovir; d4T stavudine; ddI didanosine; ABC abacavir; AZT zidovudine; FTC emtricitabine; RAL raltegravir; MVC maraviroc; ENF enfuvirtide.
